Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Major Depressive Disorder (MDD), Depress...
Phase NA
Enrollment 214
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aimed to evaluate the efficacy and safety of fecal microbiota transplantation (FMT) in patients with major depressive disorder (MDD) who exhibit suboptimal early response to antidepressant treatment. Additionally, it sought to investigate the impact of FMT on biological indicators, including intestinal microbiota and metabolites, in individuals with MDD

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Biological: FMT capsule — The experimental group will maintain escitalopram treatment and take 1.0 g of FMT capsules orally with breakfast every day for 4 weeks.
  • Drug: Escitalopram (Lexapro) — Both the experimental group and the placebo group were treated with the maximum tolerated dose of escitalopram.
  • Biological: Corn Starch capsules — The placebo group will maintain escitalopram treatment and take corn starch capsules 1.0 g orally with breakfast every day for 4 weeks.

Primary Outcomes

  • The differences in efficacy(HAMD-17 score reduction rate ≥50%) between the two groups (Baseline, Week 4, Week 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-01
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 214 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Gang Wang
Collaborators: Shandong Daizhuang Hospital, Tianjin Anding Hospital, First Affiliated Hospital of Zhejiang University, The First Hospital of Hebei Medical University, West China Hospital, Wuhu Fourth People's Hospital
Contact Information
Study Contact:
Gang Wang
86 + 010-86430066
Gang Wang
86 + 010-86430066
Beijing Anding Hospital
Interventions
  • Biological: FMT capsule — The experimental group will maintain escitalopram treatment and take 1.0 g of FMT capsules orally with breakfast every day for 4 weeks.
  • Drug: Escitalopram (Lexapro) — Both the experimental group and the placebo group were treated with the maximum tolerated dose of escitalopram.
  • Biological: Corn Starch capsules — The placebo group will maintain escitalopram treatment and take corn starch capsules 1.0 g orally with breakfast every day for 4 weeks.
Study Locations (9 sites)
Wuhu Fourth People's Hospital, Wuhu, Anhui 241002 China
Beijing Anding Hospital, Beijing, Beijing Municipality 100088 China
Nangfang Hospital Affiliated of Southern Medical University, Guangzhou, Guangdong 510450 China
The First Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000 China
Shandong Daizhuang Hospital, Jining, Shandong 272000 China
West China Hospital Affiliated of Sichuan University, Chengdu, Sichuan 610041 China
Tianjin Anding Hospital, Tianjin, Tianjin Municipality 300202 China
The Second People's Hospital of Dali Bai Autonomous Prefecture, Dali, Yunnan 671003 China
The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang 310000 China
Eligibility Criteria
Inclusion Criteria (All 8 criterion are met): * Outpatient or inpatient, aged 18 to 65 years (inclusive), regardless of gender; * At the start of the screening phase, participants must meet the Diagnostic and Statistical Manual of Mental Disorders-fifth edition (DSM-5) diagnostic criteria for recurrent major depressive disorder (MDD) or single-episode MDD; * At the start of the screening phase, participants' score on the 17-item Hamilton Depression Rating Scale (HAMD-17) must be ≥ 17; * At the start of the screening phase, participants have not been treated with medication for their current depressive episode; * At the start of the screening phase, participants are intended to be treated with a single antidepressant medication, Escitalopram; * The HAMD-17 score after two weeks of treatment with the maximum tolerated dose of escitalopram was reduced by less than 20% compared with the HAMD-17 score at screening; * Participants must have an education level above primary school and be able to understand the content of the scale; * Participants sign the informed consent form. Exclusion Criteria (Exclude if 1 criterion is met): * According to DSM-5 criteria, currently or previously diagnosed as bipolar disorder, neurodevelopmental disorder, neurocognitive disorder, schizophrenia spectrum and other psychotic disorders, substance-related and addiction disorders; * Accompanied by significant psychotic symptoms (delusions, hallucinations, etc.); * The patient currently has severe or unstable central nervous system, cardiovascular, respiratory, liver, kidney, endocrine, blood system or other system diseases, and the researcher believes that the patient is not suitable for inclusion in this study; * The patient currently has a serious suicide risk, and the HAMD-17 suicide risk item is ≥3 points; * Suffering from inflammation-related diseases; * Suffering from gastrointestinal infections, tumors and other structural abnormalities of the digestive system, including but not limited to irritable bowel syndrome, Crohn's disease, ulcerative colitis, celiac disease, etc.; * Previous history of gastrointestinal surgery; * Continuous use of antibiotics, probiotics, prebiotics or traditional Chinese medicine products for medical purposes for more than 2 weeks within 3 months before enrollment in the study; * Those who are allergic to capsule ingredients and contents; * Pregnant or lactating patients; * Patients who are unable (such as difficulty swallowing) or unwilling to swallow capsules; * Patients who received MECT treatment in the past 6 months.
Conditions Type 2 Diabetes, Diabetic Cardiomyopathy...
Phase NA
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A pragmatic, randomized clinical trial to evaluate the effect of a heart failure (HF) risk assessment and prevention strategy incorporating HF clinical risk scores (WATCH-DM) with cardiac biomarker (NT-proBNP) paired with a clinical decision support tool to implement an intensive prevention strategy among patients with high risk focused on implementation of evidence-based HF preventive therapies.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Intensive Prevention Strategy — Providers randomized to the intensive prevention strategy will receive notification about patients with diabetes who have high heart failure risk and recommendations for medical management, e-consultation, or referral to a cardiometabolic risk management program.

Primary Outcomes

  • Incident Heart Failure or All-cause death (2-year follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-10
Completion: 2027-12-15
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Texas Southwestern Medical Center
Collaborators: Roche Diagnostics GmbH
Contact Information
Study Contact:
Ambarish Pandey, MD
617-869-8957
ambarish.pandey@utsouthwestern.edu
VINAYAK SUBRAMANIAN, MD
2114-645-9868
Ambarish Pandey, MD
214-645-9868
ambarish.pandey@utsouthwestern.edu
University of Texas Southwestern Medical Center
Interventions
  • Behavioral: Intensive Prevention Strategy — Providers randomized to the intensive prevention strategy will receive notification about patients with diabetes who have high heart failure risk and recommendations for medical management, e-consultation, or referral to a cardiometabolic risk management program.
Study Locations (1 sites)
University of Texas Southwestern Medical Center, Dallas, Texas 75209 United States
Eligibility Criteria
Inclusion Criteria: * Primary Care Provider that sees diabetes patients in clinic Exclusion Criteria: * Provider does not see patients with Diabetes
Conditions Glaucoma, Open Angle Glaucoma (OAG), POA...
Phase Not Applicable
Enrollment 66
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to evaluate the long-term safety and efficacy of a modified suprachoroidal silicone tube (SST) shunt in treating patients with primary open-angle glaucoma (POAG) and pseudo-exfoliative glaucoma (PXG). The main questions it aims to answer are: Does the SST shunt maintain intraocular pressure (IOP) reduction over an extended follow-up period? What is the effect of the SST shunt on endothelial cell count (ECC) and overall corneal health? Participants will: Undergo intraocular pressure (IOP) measurements Have their endothelial cell count (ECC) evaluated Complete assessments of best corrected visual acuity (BCVA) Be assessed for C/D ratio Be monitored for adverse events or shunt-related complications over time

Design

Study type: Observational Observational model: Other Time perspective: Cross Sectional

Interventions / Regimen

  • Device: Suprachoroidal silicone tube (SST) shunt — This intervention involves implanting a modified suprachoroidal silicone tube (SST) shunt, derived from the Aurolab Aqueous Drainage Device (AADI), to lower intraocular pressure in patients with primary open-angle and pseudoexfoliative glaucoma. The SST shunt, measuring 13.0-15.0 mm with a 0.3 mm inner and 0.6 mm outer diameter, is designed to reach the posterior suprachoroidal space. Six slits near the distal end aid aqueous outflow. Implantation involves creating a scleral flap, accessing the SCS, and placing the distal end in the SCS and proximal end in the anterior chamber (AC). The shunt is secured with sutures, and viscoelastic is injected into the AC to prevent hypotony. No antimetabolites or cautery are used.

Primary Outcomes

  • Endothelial Cell Loss (From enrollment to the end of long term observational FU (average duration is 31 months with 8 months std. dev))
  • IOP Control: Success was defined as ≥20% reduction in IOP, with "complete success" for IOP control without medications, "qualified success" with medications, and "failure" for <20% IOP reduction or IOP >21 mmHg. (From enrollment to the end of long term observational FU (average duration is 31 months with 8 months std. dev))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-11-08
Completion: 2024-11-30
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 66 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Davinci LTD
Contact Information
Study Contact:
Nikoloz Labauri, MD. FVRS
+995599003744
nlabauri@yahoo.com
Nikoloz Labauri, MD. FVRS
+995599003744
nlabauri@yahoo.com
Davinci Eye Center, LTD
Interventions
  • Device: Suprachoroidal silicone tube (SST) shunt — This intervention involves implanting a modified suprachoroidal silicone tube (SST) shunt, derived from the Aurolab Aqueous Drainage Device (AADI), to lower intraocular pressure in patients with primary open-angle and pseudoexfoliative glaucoma. The SST shunt, measuring 13.0-15.0 mm with a 0.3 mm inner and 0.6 mm outer diameter, is designed to reach the posterior suprachoroidal space. Six slits near the distal end aid aqueous outflow. Implantation involves creating a scleral flap, accessing the SCS, and placing the distal end in the SCS and proximal end in the anterior chamber (AC). The shunt is secured with sutures, and viscoelastic is injected into the AC to prevent hypotony. No antimetabolites or cautery are used.
Study Locations (1 sites)
Davinci Eye Center, LTD, Tbilisi, 0160 Georgia
Eligibility Criteria
Inclusion Criteria: * Previously were treated with Suprachoroidal silicone tube shunt * Willing and able to participate in this cross sectional observational follow up * Participant capable of giving informed consent Exclusion Criteria: * Condition that could impact the ability of the participant to attend a follow-up visit as per the discretion of the investigator
Conditions Capecitabine, Hand-foot Syndrome, Electr...
Phase NA
Enrollment 220
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study hypothesizes that electroacupuncture combined with self-administered acupressure plus doctor-prescribed treatment is effective in preventing Hand-Foot Syndrome (HFS) caused by capecitabine. It aims to explore the effectiveness of this combined approach in preventing HFS in patients with malignant tumors undergoing oral capecitabine treatment. Further exploration of prevention and treatment methods may enhance the quality of life for patients during the treatment process.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Triple

Interventions / Regimen

  • Combination Product: True electroacupuncture + True self-administered acupressure — True electroacupuncture: Participants will receive two electroacupuncture treatments within the first week of each treatment cycle. The acupuncturist inserts the needle into the point and manipulates the needle until the feeling of "deqi" is achieved and reported by the participant. The electrical stimulation will be administered at a sustained frequency of 2Hz for 30 minutes. True self-administered acupressure: In weeks 2 and 3 of each treatment cycle, participants performed true self-administered acupressure, pressing each acupoint with their thumb to achieve "deqi" for three minutes.
  • Drug: Doctor-prescribed treatment — Doctor-prescribed treatment: At the beginning of capecitabine, patients will be treated with doctor-recommended medications, including oral celecoxib, topical diclofenac, and other skin protectants.
  • Combination Product: Sham electroacupuncture + Sham self-administered acupressure — Sham electroacupuncture: The sham electroacupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive acupuncture treatment without electrical stimulation same the intervention group. And avoid "deqi" sensation. Sham self-administered acupressure: Administered non-acupressure points 1 to 3cm away from the true acupressure points used in the experimental group and away from known meridians. The frequency, course duration, and overall treatment time will be the same as those in the true self-administered shiatsu group. The applied pressure does not cause a feeling of "deqi".

Primary Outcomes

  • HFS incidence rate (Compare the difference between the two groups) (Capecitabine started treatment until 12 weeks after the end of treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-08
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 220 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Affiliated Hospital of Qinghai University
Contact Information
Study Contact:
Jiuda Zhao
869716230893
jiudazhao@126.com
13327661976
jiudazhao@126.com
Qinghai University Affiliated Hospital
Interventions
  • Combination Product: True electroacupuncture + True self-administered acupressure — True electroacupuncture: Participants will receive two electroacupuncture treatments within the first week of each treatment cycle. The acupuncturist inserts the needle into the point and manipulates the needle until the feeling of "deqi" is achieved and reported by the participant. The electrical stimulation will be administered at a sustained frequency of 2Hz for 30 minutes. True self-administered acupressure: In weeks 2 and 3 of each treatment cycle, participants performed true self-administered acupressure, pressing each acupoint with their thumb to achieve "deqi" for three minutes.
  • Drug: Doctor-prescribed treatment — Doctor-prescribed treatment: At the beginning of capecitabine, patients will be treated with doctor-recommended medications, including oral celecoxib, topical diclofenac, and other skin protectants.
  • Combination Product: Sham electroacupuncture + Sham self-administered acupressure — Sham electroacupuncture: The sham electroacupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive acupuncture treatment without electrical stimulation same the intervention group. And avoid "deqi" sensation. Sham self-administered acupressure: Administered non-acupressure points 1 to 3cm away from the true acupressure points used in the experimental group and away from known meridians. The frequency, course duration, and overall treatment time will be the same as those in the true self-administered shiatsu group. The applied pressure does not cause a feeling of "deqi".
Study Locations (1 sites)
Qinghai University Affiliated Hospital, Xining, Qinghai 810000 China
Eligibility Criteria
Inclusion Criteria: 1. Sign a written informed consent form; 2. Male or female ≥ 18 years old; 3. Patients with gastrointestinal cancer or breast cancer who are diagnosed with cancer by pathology will receive capecitabine treatment for the first time according to the label; 4. The performance status of the Eastern Cancer Collaboration Group is 0-2; 5. Palliative or adjuvant chemotherapy with capecitabine (combination or monotherapy, minimum daily total dose of capecitabine 2000 mg/m\^2); 6. Expected lifespan ≥ 3 months; 7. Laboratory requirements: platelet count ≥ 100 × 10\^9/L, white blood cell count\&amp;amp;gt;3.0 × 10\^9/L, hemoglobin ≥ 10.0 g/dL, normal liver and kidney function; 8. Adequate contraception. Exclusion Criteria: 1. Previous use of capecitabine or liposome doxorubicin or any other tyrosine kinase inhibitor that may induce HFS (such as sorafenib, sunitinib, and apatinib) for chemotherapy; 2. The initial dose of capecitabine is less than 800mg/m\^2; 3. Radiation therapy or surgery should be performed within 4 weeks before the start of treatment; 4. Skin diseases that may interfere with clinical trial results; 5. Known drug/alcohol abuse; 6. Pregnant women or lactating patients; 7. Participate in another clinical trial and the patient has received the investigational drug within the last 30 days prior to the start of treatment (i.e. follow-up in the previous trial was not exclusive); 8. Known patients who are afraid of electroacupuncture stimulation or allergic to stainless steel needles or any component of capecitabine; 9. Receive any acupuncture and moxibustion treatment ,there is lymphedema in the area stimulated by acupuncture; 10. Patients with any chemotherapy- or radiotherapy-related toxicities that have not subsided to grade 2 or lower will be excluded, except for stable sensory neuropathy. 11. Any unresolved skin toxicity caused by previous chemotherapy or radiotherapy, except for hair loss, will also be grounds for exclusion.
Conditions Hypertensive Disorders of Pregnancy, Pre...
Phase PHASE4
Enrollment 76
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The objective is to conduct a double-blinded randomized controlled trial of atorvastatin vs. placebo among postpartum individuals with hypertensive disorders of pregnancy, to improve cardiovascular risk score postpartum. For this, 76 individuals with hypertensive disorders of pregnancy (HDP) will be randomized to atorvastatin 10mg or placebo, which will be started in the postpartum period after cessation of breast feeding and continued for 3 months.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Atorvastatin 10 mg — Participants will be assigned to 10 mg Atorvastatin
  • Drug: Placebo — Participants will be assigned to identical appearing placebo

Primary Outcomes

  • The 30-year Framingham Risk Score for Cardiovascular Disease (After 3 months of study treatment, up to 9 months after enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-10-03
Completion: 2026-12-15
Eligibility
Age: 20 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 76 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ohio State University
Principal Investigators:
  • Tracy C Bank, MD (PRINCIPAL_INVESTIGATOR) - Ohio State University
Contact Information
Study Contact:
Tracy C Bank, MD
614-293-2222
Tracy.Bank@osumc.edu
Maged Costantine, MD, MBA
614-293-2222
Maged.Costantine@osumc.edu
Maged Costantine, MD, MBA
614-293-2222
Maged.Costantine@osumc.edu
The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine
Interventions
  • Drug: Atorvastatin 10 mg — Participants will be assigned to 10 mg Atorvastatin
  • Drug: Placebo — Participants will be assigned to identical appearing placebo
Study Locations (1 sites)
The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine, Columbus, Ohio 43210 United States
Eligibility Criteria
Inclusion Criteria: 1. Postpartum 2. ≥ 20 years old with the ability to give informed consent 3. Diagnosis of gestational hypertension, preeclampsia prior to delivery admission, or diagnosed with preeclampsia during delivery admission, as determined by clinical team using the American College of Obstetricians and Gynecologists (ACOG) criteria. 4. English speaking Exclusion Criteria: 1. Individuals who were prescribed an 3-hydroxy-3 methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor prior to or during pregnancy, 2. Known familial hypercholesterolemia or pre-existing hyperlipidemia, specifically Low-density Lipoprotein (LDL) \>190 prior to pregnancy or diagnosis of hyperlipidemia with prescription of HMG-CoA reductase inhibitor prior to delivery, 3. Plan to breastfeed for \>= 6 months, 4. Plan for pregnancy conception in the next 6 months, 5. Incarcerated individuals, 6. Hypertensive diagnosis thought to be secondary to fetal condition, 7. Contraindications to HMG-CoA reductase inhibitor therapy or known hypersensitivity to atorvastatin or any component, 8. Active liver disease (acute hepatitis, chronic active hepatitis, unexplained persistent transaminitis (at least twice upper limit of normal serum transaminases)), 9. History of rhabdomyolysis or myopathy, 10. Human Immunodeficiency Virus (HIV) positivity, due to potential interactions between atorvastatin and HIV protease inhibitors, 11. History of solid organ transplant, due to potential interactions between atorvastatin and immunosuppressants 12. Active cancer, or 13. Current use of medications with potential drug interactions, namely cyclosporine, clarithromycin, itraconazole, HIV protease inhibitors, rifampin, and digoxin.
Conditions Vitamin D, Neoadjuvant Therapy, Breast C...
Phase NA
Enrollment 140
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This randomized controlled Phase III trial was designed to evaluate the impact of supplemental vitamin D (VD) on the efficacy and side effects of neoadjuvant therapy in patients with breast cancer.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Neoadjuvant therapy + vitamin D2 — Before the start of treatment and every 3 weeks thereafter, participants will receive injections of vitamin D2 at a dosage of 10 mg until the completion of neoadjuvant therapy. They will undergo the standard neoadjuvant regimen, which includes the 10 mg injection of vitamin D2 per cycle during the therapy. The dosage of neoadjuvant drugs may be tailored based on the physician's clinical judgment.
  • Drug: Neoadjuvant therapy — Participants will receive the standard neoadjuvant regimen during each cycle of neoadjuvant therapy. The dosage of the neoadjuvant drugs may be tailored based on the physician's clinical judgment.

Primary Outcomes

  • The objective response rate (4-6months)
  • The pathological complete response rate (4-6months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-18
Completion: 2026-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jiuda Zhao
Contact Information
Study Contact:
Jiuda Zhao
869716230893
jiudazhao@126.com
Jiuda Zhao, Dr
869716230893
jiudazhao@126.com
Qinghai University Affiliated Hospital
Interventions
  • Drug: Neoadjuvant therapy + vitamin D2 — Before the start of treatment and every 3 weeks thereafter, participants will receive injections of vitamin D2 at a dosage of 10 mg until the completion of neoadjuvant therapy. They will undergo the standard neoadjuvant regimen, which includes the 10 mg injection of vitamin D2 per cycle during the therapy. The dosage of neoadjuvant drugs may be tailored based on the physician's clinical judgment.
  • Drug: Neoadjuvant therapy — Participants will receive the standard neoadjuvant regimen during each cycle of neoadjuvant therapy. The dosage of the neoadjuvant drugs may be tailored based on the physician's clinical judgment.
Study Locations (2 sites)
Qinghai University Affiliated Hospital, Xining, Qinghai 810000 China
Qinghai University Affiliated Hospital, Xining, Qinghai 810000 China
Eligibility Criteria
Inclusion Criteria: 1. Age between 18 and 80 years, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 2. Primary diagnosis of breast cancer confirmed by preoperative pathological examination. 3. Serum 25(OH)D levels less than 20 ng/ml (50 nmol/L). 4. Patients who have not previously received chemotherapy and who plan to undergo at least 4 cycles of 5.neoadjuvant chemotherapy or combined targeted therapy. 6.Life expectancy of at least 6 months. 7.No other uncontrolled benign diseases at the time of recruitment. 8.All patients must have complete clinical medical records. 9.Willingness to voluntarily sign an informed consent form. Exclusion Criteria: 1. History of invasive breast cancer. 2. Prior systemic treatment for the treatment or prevention of breast cancer. 3. Known allergic reactions to vitamin D or calcium compounds. 4. Comorbidities that may affect vitamin D or calcium balance or bone health. 5. Vitamin D or calcium supplementation in the past 3 months. 6. Presence of other tumors. 7. Pregnant or lactating women. 8. Individuals who do not wish to participate in the study.
Conditions Essential Hypertension
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The subjects of this study were patients with essential refractory hypertension. The purpose of this study is to evaluate the safety and efficacy of superselective adrenal arterial embolization (SAAE) in patients with primary refractory hypertension and to explore the possibility of SAAE in patients with primary refractory hypertension.After the subject completes the SAAE, an 8-week follow-up will be conducted to assess the safety and effectiveness of the SAAE.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Superselective adrenal arterial embolization — Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.

Primary Outcomes

  • 24-hour mean systolic blood pressure (8 weeks after SAAE)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-01
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital of Nanchang University
Principal Investigators:
  • Yifei Dong, Doctor (PRINCIPAL_INVESTIGATOR) - Second Affiliated Hospital of Nanchang University
Contact Information
Study Contact:
Yifei the second affiliated hospital of Nanchang university, Doctor
(0791)86209562
yf_dong66@126.com
Yifei Dong, doctorate
+8613576007061
yf_dong66@126.com
The Second Affiliated Hospital of Nanchang University
Interventions
  • Procedure: Superselective adrenal arterial embolization — Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
Study Locations (1 sites)
The Second Affiliated Hospital of Nanchang University, Nanchang, China
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years, no gender restrictions; * Primary refractory hypertension: Taking three antihypertensive drugs, including a - diuretic, with an average office systolic blood pressure ≥150 mmHg measured three times; * Duration of hypertension greater than 6 months; * Standing plasma aldosterone and renin activity not below the lower limit of the unit's reference range; * Signed informed consent form. Exclusion Criteria: * Morning cortisol level \< 4.3 µg/dL; estimated glomerular filtration rate (eGFR) \< 45 mL/min/1.73 m²; serum potassium level \> 5.5 mmol/L; * Type 1 diabetes, uncontrolled hyperthyroidism, malignant arrhythmias, malignant tumors, decompensated heart failure, severe liver dysfunction, severe hematological diseases, severe obstructive sleep apnea syndrome, history of myocardial infarction, syncope, cerebral hemorrhage, or cerebral infarction within the past 3 months; * Pregnant women or those planning to conceive within the next year; * Presence of other severe organic diseases that would make the patient unable to tolerate superselective adrenal arterial embolization; * Adrenal mass with a diameter exceeding 2 cm; * Severe allergy to contrast agents; * Patients enrolled or planning to participate in other clinical studies that could impact the results of this study.
Conditions Recurrent Breast Carcinoma, Ipsilateral ...
Phase PHASE2
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Over the past decades, interest in second breast-conserving therapy (BCT) has increased due to, among others, advancements in radiotherapy techniques. Preoperative partial breast irradiation (PBI) is an experimental treatment for patients with low-risk primary breast cancer. This approach can downstage the tumor, and may possibly reduce toxicity and improve cosmetic outcomes compared to postoperative radiotherapy. This study aims to evaluate the feasibility of single-dose preoperative PBI and second breast-conserving surgery (BCS) for patients with an ipsilateral recurrent breast event (IRBE) after previous BCT. The REPEAT trial is a multicenter, prospective, single-arm trial investigating ablative single-dose preoperative PBI in patients with an IRBE. Eligible patients are ≥ 50 years, have a unifocal non-lobular invasive breast cancer ≤ 2 cm, Bloom-Richardson grade 1 or 2, estrogen receptor-positive, HER2-negative and clinically negative axillary lymph nodes. The study plans to enroll 25 patients. Radiotherapy planning will involve the use of CT and MRI in the treatment position. Single-dose PBI of 20 Gy to the tumor and 15 Gy to the surrounding 2 cm of breast tissue will be delivered using a conventional or MR-guided linear accelerator. Tumor response will be monitored preoperatively using MRI and liquid biopsies to identify biomarkers for evaluating radiosensitivity. BCS will be performed 3 weeks post-PBI. The primary endpoint is the incidence of grade 2 or higher treatment-associated acute toxicity within 90 days. Secondary endpoints include the evaluation of acute (grade 1) and late toxicity, radiologic and pathologic response, mastectomy rate, patient-reported outcomes, cosmetic outcome, local, regional and distant recurrence rates, survival outcome, and biomarkers in liquid biopsies and tumor tissue. Patients will be followed up to 5 years after PBI. This trial will evaluate the feasibility of single-dose preoperative PBI and BCS for patients with IRBE. This treatment approach is expected to minimize the irradiated volume, reduce toxicity, and improve cosmetic outcomes compared to postoperative PBI after second BCS. Identifying biomarkers for radiosensitivity will help in selection patients and tailoring treatment.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: ablative single-dose PBI — ablative single-dose PBI followed by BCS after three weeks At baseline (prior to RT) and prior to BCS, toxicity, PROMS and cosmetic outcome will be assessed. Additionally, a preoperative MRI will be performed three weeks following RT to evaluate the acute tumor response.

Primary Outcomes

  • Acute toxicity (90 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-01-01
Completion: 2026-12
Eligibility
Age: 50 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Amsterdam UMC, location VUmc
Principal Investigators:
  • Desiree HJG van den Bongard, MD PhD (PRINCIPAL_INVESTIGATOR) - Amsterdam UMC
Contact Information
Study Contact:
Janneke F van Roij, MD
+31 611094077
j.s.vanroij@amsterdamumc.nl
Lisca Wurfbain, MD
+31 625414750
l.f.wurfbain@amsterdamumc.nl
Amsterdam UMC / VU Medical Centre
Desiree HJGD Dr. van den Bongard, Dr.
Amsterdam UMC / VU Medical Centre
Interventions
  • Radiation: ablative single-dose PBI — ablative single-dose PBI followed by BCS after three weeks At baseline (prior to RT) and prior to BCS, toxicity, PROMS and cosmetic outcome will be assessed. Additionally, a preoperative MRI will be performed three weeks following RT to evaluate the acute tumor response.
Study Locations (1 sites)
Amsterdam UMC / VU Medical Centre, Amsterdam, Netherlands
Eligibility Criteria
Inclusion criteria: * WHO performance scale ≤ 2 * Females at least 50 years of age with an ipsilateral invasive breast cancer event or DCIS (i.e. recurrence, second primary) after previous breast conserving surgery and radiotherapy (for invasive breast cancer/carcinoma in situ) * Tumor characteristics: - - Tumor size ≤ 2 cm, unifocal on MRI On tumor biopsy: * Bloom-Richardson grade 1 or 2, * non-lobular invasive histological type carcinoma, * accompanying (non-extensive) DCIS is accepted within the tumor size of 2 cm on mammography and/or tumor biopsy, including no non-mass enhancement on MRI, * ER-positive and HER2-negative tumor, * No lymphovascular invasion. * Clinical node negative on PET-CT, ultrasound and MRI * No distant metastases * Repeat breast-conserving surgery is feasible, if no or mild late toxicity (no grade 2 or higher) from previous breast-conserving therapy * Adequate communication and understanding skills of the Dutch language * Written informed consent Exclusion criteria: * Ipsilateral invasive breast cancer recurrence less than 2 years after first breast conserving therapy for breast cancer or ductal carcinoma in situ * Legal incapacity * Known breast cancer mutation gene carrier * Previous ipsilateral mastectomy * Collagen synthesis disease (e.g. Osteogeneis imperfecta, Ehlers-Danlos syndrome, systemic lupus erythematosus) * Invasive lobular carcinoma * MRI absolute contraindications as defined by the Department of Radiology * Indication for treatment with neoadjuvant chemotherapy * Non-feasible dosimetric RT plan * Breast implants
Conditions Breast Cancer
Phase Not Applicable
Enrollment 2400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Psychoncological evaluation in patients diagnosed with breast cancer is often limited to psychological distress and does not include evaluation of individual resources. This assessment could contribute to implement adherence to treatment protocols and eventual post traumatic growth. This study shows a new model of psychoncological triage by screening the risk of psychological distress and coping resources in patients with non metastatic breast cancer while waiting for surgery. The evaluation is performed at the hospital after the diagnosis and by means of psychological counseling and psychodiagnostic assessment (T0) with follow up interventions along the continuum of care. Recruitment of the sample will take place in three different phases. It Includes time zero (T0) when patients are assessed during the pre-hospitalisation pathway. Time 1 (T1) patients are re-evaluated during the perioperative hospitalisation phase. Time 2 (T2) patients are re-evaluated after nine months at the end of treatment. As this phase is highly individualised for each patient and therefore susceptible to variation in duration and treatment modalities. Online psychometric revaluation will be possible. The link to the questionnaires will be sent to patients by e-mail and subsequently by telephone or in person contact. Patients are evaluated by following questionnaires. Distress Thermometer (DT). Hospital Anxiety and Depression Scale (HADS). Mini Mental of Adjustment for Cancer Scale (MINIMac) and Clinical Outcomes in Routine Assessment (CORE OM) and Post Traumatic Growth Inventory Cut off COREOM is From 10 to 15 Mild. From 15 to 20 Moderate. From 20 to 25 Mod or Severe. From 25 Severe. Scoring is from 0 is not at all and to 4 is very often/always. Reversed items 3.4. 7. 12. 19. 21. 31. 32. Higher scores correspond to greater problems. The cut off of the distress thermometer is greater than 4. The cut off oh HADS is 7. From 0 to 7 is considered normal. A score of 8 or higher indicating probable presence of a mood disorder. The miniMAC scale is a self-descriptive tool. The respondent on his or her own evaluates, using a four point scale to what extent a given statement applies to him or her at present. Each statement is rated on a scale of 1 (definitely not) to 4 (definitely yes), and the results available for each of the four strategies for dealing with the disease are 7-28 points. The higher the score, the greater the severity of the behaviors in the patient's struggle with cancer. Post Traumatic Growth Inventory. Each of the 21 items falls under one of the five factors and are scored accordingly. A summation of the scores indicates the level of post-traumatic growth. The advantage of this scale is that the categorization of scores according to the five factors are suggestive of which area of self-development is predominant in us and which area might be a little behind.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Distress Thermometer — Enrolled patients will be given a clinical psychological interview. Then they will be given an anamnestic interview and the aforementioned questionnaires will be administered.

Primary Outcomes

  • Patients assessment (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-03-31
Completion: 2029-07-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 2400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Principal Investigators:
  • Daniela Belella (PRINCIPAL_INVESTIGATOR) - Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Contact Information
Study Contact:
Daniela Belella
+390630156280
daniela.belella@policlinicogemelli.it
Daniela Belella
+390630156280
daniela.belella@policlinicogemelli.it
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOS Psicologia Clinica
Daniela Pia Rosaria Chieffo
+390630156280
danielapiarosaria.chieffo@policlinicogemelli.it
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOS Psicologia Clinica
Interventions
  • Other: Distress Thermometer — Enrolled patients will be given a clinical psychological interview. Then they will be given an anamnestic interview and the aforementioned questionnaires will be administered.
Study Locations (1 sites)
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOS Psicologia Clinica, Roma, 00168 Italy
Eligibility Criteria
Inclusion Criteria: * 18 years * candidates for surgery * candidates for adjuvant and/or neoadjuvant treatment Exclusion Criteria: * 0 to 17 years old * severe language deficits * severe barriers * Patients unable to understand and express informed consent
Conditions Breast Cancer Female, Breast Cancer, Bre...
Phase NA
Enrollment 110
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Breast Cancer (BC) is the primary oncological diagnosis in women, with the annual incidence expected to exceed 3 million new cases by 2040 due to population growth and aging. During the COVID-19 pandemic, novel methods were adopted worldwide to provide continuous patient care, including telehealth, fast-track protocols such as awake surgery in breast cancer. These innovative techniques allowed for improved access to care, and additionally reduced emissions with environmental impact, better resource utilization, and improved continuity of care, but their impact post-pandemic era has not been investigated. A current issue is the environmental impact of hospitals, particularly operating rooms, as it has been analysed that 25-30% of hospital waste comes from these areas. A Breast Green Surgery protocol (BuGS protocol) has been designed to reduce Breast Surgery Impact of care, evaluating for the synergistic effect of different procedure for the first time on classic Clincal Outcome, Patients' Reported Outcome Measure (PROM), and Environment Related Outcome Measure (EROM) in breast cancer surgery. Main hypothesis is that BuGs protocol will provide a significant reduction in carbon footprint of care (EROM) without impacting clinical outcome and PROMs.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Green Breast Surgery Protocol — A perioperative protocol aiming at reducing environmental impact of surgery, and fast recovery protocol to reduce hospitalization.

Primary Outcomes

  • 24 h Post-operative pain at rest (24 hours after surgery)
  • 24 h Post-operative dynamic pain (24 hours after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-07-01
Completion: 2025-01-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 110 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Rome Tor Vergata
Principal Investigators:
  • Gianluca Vanni, PhD (PRINCIPAL_INVESTIGATOR) - University of Rome Tor Vergata
  • Oreste Claudio Buonomo, Full Prof (STUDY_CHAIR) - University of Rome Tor Vergata
Contact Information
Study Contact:
Oreste Claudio Buonomo, Full Prof
3395685883
marco.materazzo@ptvonline.it
Marco Materazzo, PhD Fellow
3395685883
marco.materazzo@ptvonline.it
Oreste Claudio Buonomo, Full Professor
06209088350
o.buonomo@inwind.it
Università degli Studi di Roma Tor Vergata
Interventions
  • Procedure: Green Breast Surgery Protocol — A perioperative protocol aiming at reducing environmental impact of surgery, and fast recovery protocol to reduce hospitalization.
Study Locations (1 sites)
Università degli Studi di Roma Tor Vergata, Roma, 00133 Italy
Eligibility Criteria
Inclusion Criteria: * Patients candidates for Breast Conserving Treatment * ASA score I-II * Availability to Telehealth assessment in the postoperative period Exclusion Criteria: * Drug addiction * contraindication for locoregional ultrasound-guided procedure (e.g., local infection, allergy to LA) * chronic pain under treatment * pregnancy * No follow-up planned in our facility
Conditions Solid Tumor, Colon Carcinoma, Rectal Car...
Phase EARLY_PHASE1
Enrollment 32
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

VARTUTRACE is a first-in-human PET/CT molecular imaging study in patients with solid tumors. This study will investigate the biodistribution and pharmacology of two antibody fragments binding oncofetal Chondroitin Sulfate (CS). Oncofetal CS are tumor-specific carbohydrate motifs present in proteoglycans and identified by VAR2 Pharmaceuticals as expressed during fetal development. Oncofetal CS reappears in the vast majority of cancers while remaining largely absent from normal tissues. VAR2 Pharmaceuticals recently developed antibodies specific for oncofetal CS. VARTUTRACE uses two of these as radiolabeled antibody fragments to study biodistribution, tumor accumulation, pharmacodynamics and clearance pathways in a diverse patient population.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Biological: 89Zr-DFO-N-Suc-F8scFv — 89-Zirconium labeled short-chain variable fragment F8 targeting oncofetal CS.
  • Biological: 89Zr-DFO-N-Suc-C9scFv — 89-Zirconium labeled short-chain variable fragment C9 targeting oncofetal CS.
  • Radiation: PET/CT scan — IMP administration will be followed by PET/CT scans on day 1, 2 and 4.

Primary Outcomes

  • Biodistribution and pharmacokinetics of the radiolabeled IMP (Day 1, 2, and 4 after dosing)
  • Tumor-specific uptake of the IMP (Day 1 - 7 after dosing)
  • Incidence of treatment emergent adverse events (AE) (safety and tolerability) (Study duration (up to 56 days))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2024-12-10
Completion: 2026-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 32 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Var2 Pharmaceuticals
Collaborators: TRACER Europe BV
Principal Investigators:
  • Gooitzen van Dam, MD, PhD (PRINCIPAL_INVESTIGATOR) - TRACER Europe B.V.
Contact Information
Study Contact:
Anne-Fleur Verhaar, MD
0031622989025
anne-fleur@tracercro.com
Noortje van Dijk, Msc
noortje@tracercro.com
Anne-Fleur Verhaar, MD
0031622989025
anne-fleur@tracercro.com
University Medical Center Groningen (UMCG)
Interventions
  • Biological: 89Zr-DFO-N-Suc-F8scFv — 89-Zirconium labeled short-chain variable fragment F8 targeting oncofetal CS.
  • Biological: 89Zr-DFO-N-Suc-C9scFv — 89-Zirconium labeled short-chain variable fragment C9 targeting oncofetal CS.
  • Radiation: PET/CT scan — IMP administration will be followed by PET/CT scans on day 1, 2 and 4.
Study Locations (1 sites)
University Medical Center Groningen (UMCG), Groningen, Provincie Groningen 9713GZ Netherlands
Eligibility Criteria
General Inclusion Criteria: 1. Willing to adhere to the prohibitions and restrictions specified in this protocol. 2. Capable of giving signed informed consent (voluntarily), indicating that the patient understands the purpose and procedures required for the study and is willing to comply with the requirements and restrictions listed in the informed consent form and in this protocol. 3. Patients aged ≥ 18 years at moment of signing informed consent form. 4. Life expectancy of \> 12 weeks. 5. ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1. 6. BMI ≥ 18.0 and ≤ 35.0 kg/m2 and weight at least 50 kg and no more than 120 kg at screening. 7. Overtly healthy based on medical history, physical findings, vital signs, ECG at the time of screening, as judged by the Investigator. Note: one retest of vital functions and ECG is allowed within the screening window. 8. Adequate liver- and kidney function, defined by the following laboratory results obtained during screening visit: * AST, ALT, and alkaline phosphatase ≤ 2.5x the upper limit of normal (ULN) as determined by the UMCG laboratory reference values. * Serum bilirubin ≤ 2.0x ULN as determined by the UMCG laboratory reference values. Patients with known Gilbert disease who have serum bilirubin level ≤ 3x ULN may be enrolled. * INR or APTT ≤ 1.5x ULN as determined by the UMCG laboratory reference values. This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose. * eGFR (based on plasma-creatinine) = \>30 mL/min. * Serum albumin \>35 g/L. 9. No other clinically significant laboratory abnormalities as determined by the investigator. Note: one retest of lab tests is allowed within the screening window. 10. Female patients should be at least 1 year post-menopausal (amenorrhea \>12 months and/or follicle-stimulating hormone \>30 mIU/mL) at screening or surgically sterile (bilateral oophorectomy, hysterectomy, or tubal ligation). 11. Male subjects who are sexually active with a female partner of childbearing potential must agree to the use of an effective method of birth control, and must not donate sperm, until 3 months after administration of 89Zr-DFO-N-Suc-scFv (F8 or C9). Medical inclusion Criteria: Colon Carcinoma: 1. Patients diagnosed with colon carcinoma stage I-IV, according to the 8th edition of the TNM-classification. 2. Histologically confirmed diagnosis of colon carcinoma. 3. Neo-adjuvant treatment according to the standard of care. Rectal Carcinoma: 1. Patients diagnosed with rectal carcinoma stage I-IV, according to the 8th edition of the TNM-classification. 2. Histologically confirmed diagnosis of rectal carcinoma. 3. Neo-adjuvant treatment according to the standard of care. Bone- and soft-tissue sarcoma 1. Patients diagnosed with a bone- or soft-tissue sarcoma stage I-IV, according to AJCC staging for Sarcoma. 2. Histologically confirmed diagnosis of sarcoma. 3. Neo-adjuvant treatment according to the standard of care. Breast carcinoma 1. Patients diagnosed with breast carcinoma stage I-IV, according to the 8th edition of the TNM-classification. 2. Histologically confirmed diagnosis of breast carcinoma. 3. Neo-adjuvant treatment according to the standard of care. Lung Carcinoma: 1. Anticipated diagnosis of Non-Small Cell Lung Carcinoma (NSCLC) stage I-IV, according to the 8th edition of the TNM-classification, based on imaging modalities such as (PET)/CT or based on cytology. 2. Neo-adjuvant treatment according to the standard of care. Head and Neck Squamous Cell carcinoma (HNSCC): 1. Patients diagnosed with HNSCC of the oral cavity, oropharynx, nasal cavity, nasopharynx, hypopharynx and larynx. 2. Histologically confirmed diagnosis of HNSCC. 3. Neo-adjuvant treatment according to the standard of care. Oesophageal and gastric carcinoma: 1. Patients diagnosed with oesophagus carcinoma stage I-IV according to the 7th edition of the TNM-classification. 2. Patients diagnosed with gastric carcinoma stage I-IV according to the 7th edition of the TNM-classification. 3. Histologically confirmed diagnosis of oesophageal- or gastric carcinoma. 4. Neo-adjuvant treatment according to the standard of care. Pancreas carcinoma: 1. Anticipated diagnosis of pancreas carcinoma stage I-IV according to the 8th edition of the TNM-classification, based on imaging modalities such as (PET)/CT or based on cytology. 2. Histologically or cytologically confirmed diagnosis of pancreas carcinoma. 3. Neo-adjuvant treatment according to the standard of care. Bladder carcinoma: 1. Patients diagnosed with invasive bladder carcinoma stage I-IV according to the 7th edition of the TNM-classification. 2. Histologically confirmed diagnosis of bladder carcinoma. 3. Neo-adjuvant treatment according to the standard of care. Glioblastoma: 1. Anticipated diagnosis of a high-grade glioma (glioblastoma, grade 4 according to the WHO classification) based on imaging modalities such as MRI and/or CT or a biopsy. 2. Karnofsky performance status of at least 70%. 3. Neo-adjuvant treatment according to the standard of care. General Exclusion Criteria: 1. Behavioral or cognitive impairment or psychiatric disease that, in the investigator's opinion, affects the patient's ability to understand and cooperate with the study protocol. 2. Insufficient venous access for the study procedures. 3. Close affiliation with the investigator, e.g. a close relative of the investigator, dependent person (e.g. employee or student), employee of the department of surgery or nuclear department of the UMCG,TRACER or affiliates. 4. Any finding in the medical examinations or medical history giving, in the opinion of the investigator, reasonable suspicion of a disease or condition that makes treatment with the investigational drug unadvisable, or that might affect interpretation of the results of the study or render the patient at high risk for treatment complications. 5. Participation in an interventional clinical study within 30 days prior to tracer administration that involved treatment with any drug (excluding vitamins and minerals) or medical device. Medical Exclusion Criteria: 1. The existence of a second concomitant active malignancy or treatment for a second malignancy within 1 year prior to IMP-administration that is not a solid tumor indication included in the VARTUTRACE study, except for localized basal or squamous cell cancer that has been cured at least 90 days before screening. 2. Cardiac impairment with an estimated LVEF \<35 % Prolonged QTcF (\>450 ms), cardiac arrhythmias or any clinically significant abnormalities in the resting ECG at the time of screening, as judged by the investigator. 3. Any abnormalities in the vital signs of the patient, as judged by the investigator, as a result of which the patient cannot participate. Note: One retest of vital functions is allowed within the screening window. 4. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications. 5. Major surgical procedure other than for the included diagnosis within four weeks before IMP administration. Disease-related procedures, e.g. the placement of a port-a-cath, placement of a drain, ERCP, are allowed. 6. Current evidence or history of bacterial, viral or fungal infections within 7 days before 89Zr-DFON-Suc-scFv (F8 or C9) administration as judged by the Investigator. * T \> 38.0°C or lab confirmed viral/bacterial/fungal infection (PCR) or symptoms suggestive of an infection) * Received oral or IV antibiotics within \<7 days before administration. 7. Any planned major surgery within the duration of the study (until follow-up visit) that is not related
Conditions Breast Cancer
Phase NA
Enrollment 36000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Women with extremely dense breasts (nearly all glandular and connective tissue, little fatty tissue) have a 3-6 times higher risk of breast cancer than women with very low breast density. Moreover, due to the masking effect of the dense tissue, any breast tumours present are more difficult to detect in these women. With the results of the DENSE trial, the investigators showed that among women with extremely dense breasts, a combination of MRI and mammography could detect tumours earlier than mammography only. As the implementation of MRI in the screening program induces considerable costs and capacity requirements, the Dutch Ministry of Health would like to investigate whether cheaper and acceptable alternatives can be implemented more easily. In the DENSE-2 study, proposed here, we will investigate contrast-enhanced mammography and an abbreviated form of MRI as alternatives, in a large-scale randomized trial, within the current population-based screening program.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Contrast-enhanced mammography (CEM) — This intervention group receives supplemental screening with CEM after a negative screening result within the Dutch National Breast Cancer Screening program
  • Diagnostic Test: Abbreviated MRI (AB-MRI) — This intervention group receives supplemental screening with AB-MRI after a negative screening result within the Dutch National Breast Cancer Screening program

Primary Outcomes

  • Interval Cancer Rate (0 - 3 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-11
Completion: 2031-09-01
Eligibility
Age: 49 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 36000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: C.H. van Gils
Collaborators: University Medical Center Groningen, Ziekenhuisgroep Twente, Radboud University Medical Center, Rijnstate Hospital, Zuyderland Medical Centre, Maastricht University Medical Center, Elisabeth-TweeSteden Ziekenhuis, Catharina Ziekenhuis Eindhoven, Jeroen Bosch Hospital, Erasmus Medical Center, Albert Schweitzer Hospital, St. Antonius Hospital, Antoni van Leeuwenhoek Hospital, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Bevolkingsonderzoek Nederland, Borstkankervereniging Nederland
Principal Investigators:
  • Carla van Gils, Prof. (PRINCIPAL_INVESTIGATOR) - UMC Utrecht
Contact Information
Study Contact:
Carla van Gils, Prof
0031-88-7568181
dense-2@umcutrecht.nl
Evelyn Monninkhof, Dr.
e.monninkhof@umcutrecht.nl
Sophie van Grinsven, Msc.
0031-88-7568181
dense-2@umcutrecht.nl
UMC Utrecht
Interventions
  • Diagnostic Test: Contrast-enhanced mammography (CEM) — This intervention group receives supplemental screening with CEM after a negative screening result within the Dutch National Breast Cancer Screening program
  • Diagnostic Test: Abbreviated MRI (AB-MRI) — This intervention group receives supplemental screening with AB-MRI after a negative screening result within the Dutch National Breast Cancer Screening program
Study Locations (1 sites)
UMC Utrecht, Utrecht, Netherlands
Eligibility Criteria
Inclusion Criteria: * Participant in the Dutch population-based breast cancer screening program with a negative mammography result (BI-RADS classification 1 or 2). * Extremely dense breast tissue (assessed with Quantra software, category D). * Age between 49-72 years (women are invited to the Dutch screening program in the year they turn 50, so the minimum age is 49 years. The maximum age for inclusion is 72 years to ensure that women can still participate in a second round of supplemental screening). * Living in the service area (travel distance of up to 60 km) of the 15 participating hospitals. * Absence of breast implants (Quantra cannot provide an accurate density determination for breasts with implants). * No objection to data sharing. * Not a participant in the DENSE trial or STREAM trial (participants in the DENSE and STREAM trials are known to the Dutch screening organization). Exclusion Criteria: The additional exclusion criteria for the intervention arms are checked after randomization and recruitment (this order is due to the pre-randomization design): * Presence of in-body metals (only for AB-MRI, this involves specific metals and is asked by telephone). * Previous allergic reaction to the provided contrast agent. * Renal insufficiency (glomerular filtration rate \<30 ml/min) (only for CEM, is checked for with questionnaire I and possibly renal function measurement). * Severe claustrophobia (only for AB-MRI). * Severe obesity (weight \>150 kg) (only for AB-MRI).